Karen Knudsen: Parker Institute for Cancer Immunotherapy is an organization built to make bold moves in science
Karen Knudsen, CEO of Parker Institute for Cancer Immunotherapy, posted on LinkedIn:
“As I wrap up my second week as CEO of Parker Institute for Cancer Immunotherapy, one thing is clear: this is an organization built to make bold moves in science, and we are hitting the ground running!
I was thrilled to welcome visionary friend and colleague Dr. Ira Mellman as our new President of Research at this week’s PICI Spring Retreat.
Ira is a pioneering force in immunology and cancer biology, and his arrival comes at a pivotal moment for us at PICI.
IMHO, what sets us apart is our “bench to bedside to business” pipeline, starting with our ability to unify leading scientists, biotech visionaries, and investors around the shared mission. Accelerating cures through translational science and strategic collaboration is simply in our DNA! With Ira’s leadership, we are doubling down on our ability to turn breakthrough science into real-world impact.
This is just the beginning! More to come…”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023